Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Gains from Sales and Divestitures (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Gains from Sales and Divestitures for 8 consecutive years, with $48133.0 as the latest value for Q1 2025.

  • For Q1 2025, Gains from Sales and Divestitures fell 17.84% year-over-year to $48133.0; the TTM value through Mar 2025 reached $48133.0, down 17.84%, while the annual FY2023 figure was $68055.0, 38.16% down from the prior year.
  • Gains from Sales and Divestitures hit $48133.0 in Q1 2025 for Crescent Biopharma, down from $58581.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $189792.0 in Q3 2021 and bottomed at $48133.0 in Q1 2025.
  • Average Gains from Sales and Divestitures over 5 years is $91741.4, with a median of $68055.0 recorded in 2023.
  • Year-over-year, Gains from Sales and Divestitures soared 82.32% in 2021 and then crashed 42.02% in 2022.
  • Crescent Biopharma's Gains from Sales and Divestitures stood at $189792.0 in 2021, then plummeted by 42.02% to $110050.0 in 2022, then tumbled by 38.16% to $68055.0 in 2023, then dropped by 13.92% to $58581.0 in 2024, then fell by 17.84% to $48133.0 in 2025.
  • According to Business Quant data, Gains from Sales and Divestitures over the past three periods came in at $48133.0, $58581.0, and $58581.0 for Q1 2025, Q3 2024, and Q2 2024 respectively.